Haiping Jiang (Nong Xu)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Topics

Combination Therapy

Squamous Cell Carcinoma

Brain Metastases

Top Venues

Cancer immunology, immunotherapy : CII

Current oncology (Toronto, Ont.)

Journal of translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Yulong Zheng, Jian Qing Zhu, Jianping Xiong, Ou Jiang, Hong Wang, Yanru Xie, Yuefen Zhou, Haiping Jiang
Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204). Cancer 130 (12) (2024)
Yulong Zheng, Jian Qing Zhu, Jianping Xiong, Ou Jiang, Hong Wang, Yanru Xie, Yuefen Zhou, Haiping Jiang
Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204). Cancer 130 (12) (2024)
Yulong Zheng, Jian Qing Zhu, Jianping Xiong, Ou Jiang, Hong Wang, Yanru Xie, Yuefen Zhou, Haiping Jiang
Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204). Cancer (2024)
Mingyu Wan, Yongfeng Ding, Xiaolu Ma, Xiaoyu Chen, Xin Xu, Chenyu Mao, Jiong Qian, Cheng Xiao, Haiping Jiang, Yulong Zheng, Li Song Teng, Haiping Jiang
The Memorial Sloan Kettering Prognostic Score: Correlation with survival in patients with advanced gastric cancer. Cancer medicine (2023)
Xiaolu Ma, Yongfeng Ding, Jiong Qian, Mingyu Wan, Ning Li, Chenyu Mao, Cheng Xiao, Haiping Jiang, Yulong Zheng, Luntao Wu, Xiaoyu Chen, Haiping Jiang
Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy. Current oncology (Toronto, Ont.) 29 (11) (2022)
Haiping Jiang, Yulong Zheng, Jiong Qian, Chenyu Mao, Xin Xu, Ning Li, Cheng Xiao, Huan Wang, Lisong Teng, Hui Zhou, Shuyan Wang, Donglei Zhu, Tao Sun, Yingying Yu, Wenying Guo, Nong Xu
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study. Cancer immunology, immunotherapy : CII 70 (3) (2020)
Yulong Zheng, Yongfeng Ding, Qifeng Wang, Yifeng Sun, Xiaodong Teng, Qiqi Gao, Weixiang Zhong, Xiaofeng Lou, Cheng Xiao, Chengshu Chen, Qinghua Xu, Haiping Jiang
90-gene signature assay for tissue origin diagnosis of brain metastases. Journal of translational medicine 17 (1) (2019)